HAS Healthcare Advanced Synthesis launches as


AT Health Advanced Synthesis throw like an independent company

Biasca, Switzerland, January 13, 2022 – HAS Healthcare Advanced Synthesis SA (the “Company”), a contract development and manufacturing organization (CDMO) providing customized, proprietary and high-quality solutions to its healthcare customers, today announces its launch as an independent business. Originally created as part of the Helsinn Group by the Braglia family, as Helsinn Advanced Synthesis SA, the company has been a CDMO since 1984.

The transition to an independent private company reflects the company’s growth over the past few years and the desire to fully focus the company on delivering the best CDMO standards to its healthcare customers. As a subsidiary of the new company 3B Future Holding SA (also 100% owned by the Braglia family) and supported by a team of passionate senior managers with extensive experience and skills in contract manufacturing for the pharmaceutical industry, HAS Healthcare Advanced Synthesis believes it is well positioned to serve its customers as an innovative, state-of-the-art manufacturing facility. The company’s management team will remain in place and Waldo Mossi, previously managing director, has been appointed as managing director. Mossi, who has been with the company for 27 years, has led the company as Managing Director for the past 8 years.

The dedicated HAS Healthcare Advanced Synthesis team will continue to offer exclusive and personalized services to its customers, including the development and manufacturing of Active Pharmaceutical Ingredients (APIs), cGMP Advanced Intermediates, High Potency APIs (HPAPI) and anticancer compounds, and to support its customers with their analytical and regulatory requirements. Over the years, the Company has always strived to provide cutting-edge service to its customers in their large-scale projects and has done so by investing in innovative technologies within its factories while striving to reduce the impact of its activities on the environment. Go forward,

HAS Healthcare Advanced Synthesis intends to build new laboratories to further strengthen its pharmaceutical offer and anticipate future regulatory demands.

To consult the new HAS Healthcare Advanced Synthesis website, please follow this link.

Waldo Mossi, CEO from HAS Santé Advanced Synthesis, commented“We are delighted to announce this exciting new milestone for HAS Healthcare Advanced Synthesis. Having spent the last decade developing our facilities, with a total investment of over CHF 100 million, we are excited about the prospect of supporting our customers and all their manufacturing needs as an independent business. Our passion to deliver the best results will remain unchanged, underpinned by the experience and know-how synonymous with our team. I am honored to serve as CEO and to have had this golden opportunity to lead HAS Healthcare Advanced Synthesis through this important milestone for the company.

Ricardo Braglia, President of HAS Health Advanced Synthesis advice, commented“The Braglia family is proud to see HAS Healthcare Advanced Synthesis officially launching as an independent Helsinn company. This speaks to the team’s continued commitment to delivering tailored solutions to its customers and its focus on quality, reliability, supply chain management and safety. I would like to personally thank Waldo Mossi for his 27 years of service and am delighted that he has accepted the new role of CEO. Waldo, alongside the HAS Healthcare Advanced Synthesis Board, will form the leadership team to guide the company through its strategic next steps as a full-service CDMO delivering high-quality, proprietary and customized solutions to its healthcare clients. health.


About the HAS Santé advanced summary

HAS Healthcare Advanced Synthesis is a full service CDMO committed to providing a reliable, first class and tailored offering. The Company develops and manufactures Active Pharmaceutical Ingredients (APIs), cGMP Advanced Intermediates, High Potency APIs (HPAPIs) and anti-cancer compounds for its customers, from clinical supply to commercial supply, on a proprietary basis.

The production facility is located in Biasca, Switzerland, and was established in 1984. The site is regularly inspected by the FDA, SwissMedic and other global regulatory bodies. The scale of production ranges from grams to tens of kilograms for HPAPIs and anti-cancer compounds, from kilograms to tens of tons (APIs) in facilities fully dedicated to cGMP manufacturing.

Please visit our new website: https://www.hashealthcare.com

For more information:
HAS Health Advanced Synthesis Media Contact

Biasca, Switzerland

Giulia Rigonalli

Tel: +41 (0) 91 873 94 00

Email: mediarelations@hashealthcare.com

For more information, please visit https://www.hashealthcare.com


Comments are closed.